Skip to content

Serum Elafin and Vascular Affection in Behcet Disease

Serum Elafin: A Biomarker in Behcet Disease and Its Relation to Vascular Involvement and Disease Activity

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06272929
Enrollment
90
Registered
2024-02-22
Start date
2024-03-01
Completion date
2025-04-01
Last updated
2024-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet Disease and Vascular Affection

Brief summary

To measure the level of serum elafin in patients with BD. To assess the relation between serum elafin levels and disease activity. To evaluate the vascular complications in BD and determine their relationship with disease activity. To assess the correlation between serum elafin and vascular affection and their relation with disease activity.

Detailed description

Behçet's disease (BD) is a chronic, multisystemic, inflammatory disease characterized by recurrent oral and genital ulcers and multiple systemic involvements. Elafin is a serine protease inhibitor produced mainly by epithelial cells. Its expression is upregulated by proinflammatory cytokines such as IL-1β and TNF-α that are potent stimulants of neutrophil activation, it counteracts the destructive effects of neutrophil elastase .Interestingly, previous reports documented the role of serum elafin in the pathogenesis of BD.In fact, vascular complications may be one of the earliest manifestations leading to the diagnosis of BD. There is no reliable tool to identify vascular wall inflammation in BD, except for detecting intravascular thrombosis with ultrasonography (US). Previous studies investigated arterial vessel wall thickness with US (mostly in carotid arteries) in BD . Venous wall inflammation presents with deep vein thrombosis and superficial thrombophlebitis . It was stated that lower extremity vein wall thickness (VWTs)was increased in BD patients independently of vascular activity and important in the diagnosis . However, studies in the literature evaluated only lower extremity VWTs, whereas the relationship of VWT with disease activity has not been emphasized .

Interventions

DEVICEdoppler ultrasound

doppler US

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 45 Years

Inclusion criteria

Patients diagnosed as BD. Age of all participants (20-45) years.

Exclusion criteria

Age \<20 or \>45 years. Other autoimmune diseases. Cardiovascular diseases (heart failure, myocardial ischemia). Possible related risk factors (e.g. diabetes, dyslipidemia, smoking). chronic conditions (e.g. chronic kidney disease, malignancy, autoimmune diseases).

Design outcomes

Primary

MeasureTime frameDescription
Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.within one yearMeasuring the level of serum Elafin in patients with BD in comparison to healthy participants.

Contacts

Primary ContactLobna Amer, MD
lobnaamer20@gmail.com01019313530

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026